Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- Blood donors help cancer patient beat the odds on February 18, 2019 at 10:24 pm
In Hand's case, it progressed quickly. Within days, she was told she'd developed acute myeloid leukemia or AML. "I was stunned, really, when I got the diagnosis," Hand remembers. "My husband was stunn... […]
- I am dying of Leukemia on February 18, 2019 at 5:05 pm
It is the most common type of leukemia overall, and occurs about twice as often in men as in women. 3. Acute myeloid leukemia (AML) causes uncontrolled production of another type of white blood cell c... […]
- New Approach to Treat Leukemia Discovered on February 18, 2019 at 2:17 am
Acute myeloid leukemia (AML), the most common form of acute leukemia, is characterized by an increase of malignant myeloid progenitor cells at the expense of mature blood cells. Only twenty-five perce... […]
- Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML on February 15, 2019 at 2:52 am
Vor plans to use the proceeds from the financing to advance its lead HSC-based candidate for the treatment of acute myeloid leukemia (AML) towards the clinic, and to further build its pipeline to trea... […]
- Vor Biopharma raises $42M in Series A round to advance AML cell therapy toward clinic on February 14, 2019 at 8:40 am
The company said it would use the funding to advance its hematopoietic stem cell-based therapy candidate for treating acute myeloid leukemia toward the clinic and further build its therapy pipeline. […]
- 29-Year-Old's Leukemia Fight Highlights Hurdles Certain Ethnicities Face In Finding Bone Marrow Match on February 14, 2019 at 6:35 am
The search is on for a bone marrow transplant for a 29-year-old journalist from Orange County, California, who is in the hospital with acute myeloid leukemia, an aggressive form of the cancer. Liyna A... […]
- Novel AML Strategies Aim to Restore Regulatory Gene Functions on February 13, 2019 at 1:09 pm
The disseminated malignancy with the best overall survival today is acute promyelocytic leukemia (APL), a rare genetic subtype of de novo acute myeloid leukemia (AML), which accounts for less than 10% ... […]
- New Study to Focus on Unique Needs of Acute Myeloid Leukemia Patients on February 11, 2019 at 9:44 am
WASHINGTON: The Cancer Support Community (CSC), a global nonprofit, is launching a unique research study focused on individuals diagnosed with Acute Myeloid Leukemia (AML), a cancer of the blood and b... […]
- The Future of AML Therapy: Cause for Optimism on February 7, 2019 at 9:41 am
Daniel A. Pollyea, MD, MS: In my view, the most promising therapies for AML [acute myeloid leukemia] are those that affect the leukemic stem cell compartment. Leukemia stem cells are the root cause of ... […]
- Latest Acute Myeloid Leukemia Treatment Therapeutic Survey Report 2019: Technology, Treatment, Market Share, Growth Analysis and Synthesis, Forecast on February 7, 2019 at 4:57 am
Acute Myeloid Leukemia Treatment Market Information; by Disease Type (Myeloblastic, Promyeloctic, Myelomonocytic, Monocytic, Erythroleukemia, Megakaryocytic); by Treatment (Chemotherapy (Induction, Po... […]
via Bing News